Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4362996 | 0.83 | ALDH1A1 (0.42) | KIF11GAAKMT2AMEN1HTT | |
| SCHEMBL4367360 | 0.82 | KMT2A (0.38) | HPGDSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL4367354 | 0.82 | KMT2A (0.38) | HPGDSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL6306727 | 0.80 | ALDH1A1 (0.47) | KIF11SMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL18705415 | 0.77 | ALDH1A1 (0.44) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL2490295 | 0.77 | KCNN4 (0.61) | KIF11SMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL4374354 | 0.76 | MAPT (0.48) | KMT2AMEN1ALDH1A1CASRMAPT | |
| SCHEMBL4374348 | 0.76 | MAPT (0.48) | KMT2AMEN1ALDH1A1CASRMAPT | |
| SCHEMBL6306726 | 0.76 | ALDH1A1 (0.36) | HPGDSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL2489143 | 0.75 | ALDH1A1 (0.45) | GAAKMT2AMEN1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919441-B2 | Polyamide-oligonucleotide derivatives, their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20030203359-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH | 2003-10-30 | — | — | US | disclosed |
| US-6063571-A | SYNTHESIZING NUCLEOTIDE SEQUENCES; OBTAINING NUCLEOTIDE SEQUENCE TEMPLATE, HYBRIDIZING OLIGONUCLEOTIDE, SYNTHESIZING NUCLEOTIDE SEQUENCES; FOR DIAGNOSIS OF CANCER, VIRAL INFECTION, AND PROPAGATION DEFECTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-05-16 | — | — | US | disclosed |
| EP-0829542-A1 | Method for amplification of nucleic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203359-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | POLRMT, POLN, POLR2H | KIF11 3335/4885HPGD 4083/4885SMN1; SMN2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.